卵巢癌临床研究新进展  

New Clinical Research Progress of Ovarian Cancer

作　　者：王静[1,2] 罗晨辉 唐雨曦[1,2] 

机构地区：[1]湖南省肿瘤医院 [2]中南大学湘雅医学院附属肿瘤医院,湖南长沙410013

出　　处：《肿瘤药学》2013年第4期242-245,258,共5页Anti-Tumor Pharmacy

摘　　要：卵巢癌是妇科三大常见的恶性肿瘤之一,病死率高居首位,关于卵巢癌的临床研究一直是近几年国际肿瘤研究的热点。目前,卵巢癌的诊治主要参考NCCN制订的《卵巢癌临床实践指南》,该指南已有2012年第二版的更新。本文主要对近两年国际和国内在卵巢癌的手术治疗、新辅助化疗、化疗用药和遗传突变的作用等几个方面的相关临床研究及未来的发展趋势作一综述。Ovarian cancer was one of the three most common malignant tumors in gynecology department. Its fatality rate ranked first and it has become the hot spot in the international cancer research in recent years. At present, the NCCN clinical practice guidelines for ovarian cancer are primarily consulted in the diagnosis and treatment of ovarian cancer. This guideline has been updated in 2012. In this paper we mainly summarized the international and domestic clinical researches on about ovarian cancer in aspects of surgical treatment, neoadjuvant chemotherapy, chemotherapy drugs and the role of genetic mutations in last two years, as well as the development trend.

关 键 词：卵巢癌 临床研究 治疗 

分 类 号：R737.31[医药卫生—肿瘤]